/
DCF Valuation
Base-case fair value
$41.17
Intrinsic $54.89 · 25% MOS
Current price: $7.03
Base-case summary
Our base-case DCF for Puma Biotechnology, Inc. (PBYI) projects 10 years of free cash flow growth at 20.0% for years 1–5 and 10.0% for years 6–10, anchored to 21.0% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $54M in trailing free cash flow, this produces an intrinsic value of $54.89 per share. A 25% safety margin gives a fair value of $41.17, suggesting the stock is currently 486% undervalued against the $7.03 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$54M
Cash & equivalents
$102M
Total debt
$16M
Shares outstanding
51M